Suven Pharmaceuticals Limited

NSEI:SUVENPHAR 株式レポート

時価総額:₹209.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Suven Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /66

Suven Pharmaceuticalsの総株主資本は₹20.5B 、総負債は₹385.8Mで、負債比率は1.9%となります。総資産と総負債はそれぞれ₹22.5Bと₹2.0Bです。 Suven Pharmaceuticalsの EBIT は₹3.5Bで、利息カバレッジ比率47.1です。現金および短期投資は₹8.2Bです。

主要情報

1.9%

負債資本比率

₹385.75m

負債

インタレスト・カバレッジ・レシオ47.1x
現金₹8.24b
エクイティ₹20.51b
負債合計₹2.03b
総資産₹22.54b

財務の健全性に関する最新情報

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07
Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03
Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04
Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13
With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08
Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

財務状況分析

短期負債: SUVENPHARの 短期資産 ( ₹12.6B ) が 短期負債 ( ₹1.1B ) を超えています。

長期負債: SUVENPHARの短期資産 ( ₹12.6B ) が 長期負債 ( ₹965.3M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: SUVENPHAR総負債よりも多くの現金を保有しています。

負債の削減: SUVENPHARの負債対資本比率は、過去 5 年間で14%から1.9%に減少しました。

債務返済能力: SUVENPHARの負債は 営業キャッシュフロー によって 十分にカバー されています ( 929.3% )。

インタレストカバレッジ: SUVENPHARの負債に対する 利息支払いEBIT ( 47.1 x coverage) によって 十分にカバーされています


貸借対照表


健全な企業の発掘